Charles O’keeffe, an Insider in Catalyst Pharmaceuticals, Inc. (CPRX), Acquired 4000 shares of the Company; Ecc Capital (ECR) Sentiment Is 0.95

Eclipse Resources Corporation (NYSE:ECR) Logo

Sentiment for Ecc Capital Corp (ECR)

Ecc Capital Corp (ECR) investors sentiment is 0.95 in Q1 2018. It’s the same as in 2017Q4. The ratio is the same, as only 39 institutional investors increased or started new holdings, while 41 cut down and sold their stock positions in Ecc Capital Corp. The institutional investors in our database now have: 62.20 million shares, up from 58.75 million shares in 2017Q4. Also, the number of institutional investors holding Ecc Capital Corp in top ten holdings was flat from 0 to 0 for the same number . Sold All: 12 Reduced: 29 Increased: 26 New Position: 13.

The stock increased 2.26% or $0.04 during the last trading session, reaching $1.59. About 475,603 shares traded. Eclipse Resources Corporation (ECR) has declined 38.43% since June 7, 2017 and is downtrending. It has underperformed by 51.00% the S&P500. Some Historical ECR News: ; 02/05/2018 – Eclipse Resources 1Q Average Net Daily Production Was 315.2 MMcfe Per Day; 20/04/2018 – DJ Eclipse Resources Corp, Inst Holders, 1Q 2018 (ECR); 02/05/2018 – Factors of Influence in 2018, Key Indicators and Opportunity within Independent Bank Group, Eclipse Resources, Stellus Capital; 26/03/2018 – ECLIPSE RESOURCES – STRATEGIC ALTERNATIVES REVIEW PROCESS HAS NOT BEEN INITIATED AS A RESULT OF RECEIVING ANY TRANSACTION PROPOSAL; 26/03/2018 – Eclipse Resources Announces Operational Update, Marcellus Type Curve Increase and Upcoming Conference Participation; 02/05/2018 – Eclipse Resources Sees About $250 M in Estimated Capital Expenditures for 2018; 09/05/2018 – Eclipse Resources Closes Above 50-Day Moving Average; 26/03/2018 – Eclipse Resources Announces Strategic and Fincl Review Initiative; 26/03/2018 – ECLIPSE RESOURCES CORP – HAS NOT SET A TIMETABLE FOR COMPLETION OF REVIEW PROCESS; 28/03/2018 – CORRECT: ECR FILES FOR 37.8M SHR SECONDARY OFFERING

Ratings analysis reveals 50% of Eclipse Resources’s analysts are positive. Out of 2 Wall Street analysts rating Eclipse Resources, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. ECR was included in 2 notes of analysts from November 21, 2016. As per Friday, December 9, the company rating was downgraded by Seaport Global Securities. KLR Group initiated Eclipse Resources Corporation (NYSE:ECR) on Monday, November 21 with “Buy” rating.

Kohlberg Kravis Roberts & Co. L.P. holds 0.19% of its portfolio in Eclipse Resources Corporation for 11.05 million shares. Jbf Capital Inc. owns 612,376 shares or 0.14% of their US portfolio. Moreover, Magnetar Financial Llc has 0.11% invested in the company for 3.10 million shares. The Pennsylvania-based Penn Capital Management Co Inc has invested 0.11% in the stock. Cortina Asset Management Llc, a Wisconsin-based fund reported 719,764 shares.

Analysts await Eclipse Resources Corporation (NYSE:ECR) to report earnings on August, 1. They expect $-0.04 earnings per share, down 100.00% or $0.02 from last year’s $-0.02 per share. After $0.02 actual earnings per share reported by Eclipse Resources Corporation for the previous quarter, Wall Street now forecasts -300.00% negative EPS growth.

Eclipse Resources Corporation, an independent exploration and production company, acquires and develops oil and natural gas properties in the Appalachian Basin. The company has market cap of $478.82 million. The firm owns interests in the Utica Shale and Marcellus Shale areas. It has a 52.83 P/E ratio. As of December 31, 2016, it had an acreage position approximating 199,000 net acres in Eastern Ohio.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. The company has market cap of $344.72 million. The Company’s product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. It currently has negative earnings. The firm is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet.

A calculated and judicious act was made by the director of Catalyst Pharmaceuticals Inc, Mr. Charles O’keeffe, on June 7, 2018, when he acquired 4,000 shares, totalling $13,222 U.S. Dollars, based on an average weighted cost of $3.3 for a share. In the last month, he also obtained 5,000 shares worth approximately $18,680 USD. Now, Charles O’keeffe has in hand a total of 522,376 shares or 0.51% of the company’s market cap (share price times the number of shares outstanding). The acquired shares were obtained on June 7, 2018 and the Form 4 that contains the source information, filed with the (SEC) can be seen here.

Since April 3, 2018, it had 3 insider purchases, and 0 sales for $139,480 activity. MCENANY PATRICK J bought $45,800 worth of stock. DENKHAUS DONALD A bought 20,000 shares worth $75,000. 5,000 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) shares with value of $18,680 were bought by O’Keeffe Charles B.

Analysts await Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report earnings on August, 8. They expect $-0.07 earnings per share, down 40.00% or $0.02 from last year’s $-0.05 per share. After $-0.06 actual earnings per share reported by Catalyst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 16.67% negative EPS growth.

The stock decreased 3.45% or $0.12 during the last trading session, reaching $3.36. About 953,604 shares traded or 7.07% up from the average. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 50.23% since June 7, 2017 and is uptrending. It has outperformed by 37.66% the S&P500. Some Historical CPRX News: ; 29/05/2018 – Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse for Lambert-Eaton Myasthenic Syndrome; 29/03/2018 – CATALYST PHARMACEUTICALS – SUBMISSION OF NDA TO U.S. FDA FOR FIRDAPSE; 29/05/2018 – Catalyst Pharmaceuticals Submission Is Supported by Positive Results From Two Phase 3 Studies; 14/03/2018 – CATALYST PHARMA: FIRDAPSE NDA TO BE RESUBMITTED BEFORE QTR-END; 29/05/2018 – CPRX FIRDAPSE GETS FDA PRIORITY REVIEW STATUS; 14/03/2018 – CATALYST PHARMACEUTICALS – BASED ON CURRENT FINANCIAL POSITION, CASH FORECAST CO BELIEVES IT HAS SUFFICIENT FUNDS TO SUPPORT OPERATIONS THROUGH 2019; 19/04/2018 – Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse(R) in MuSK Antibody Positive Myasthenia Gravis; 19/04/2018 – Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of FirdapseĀ® in MuSK Antibody Positive Myasthenia Gravis; 29/05/2018 – CATALYST PHARMACEUTICALS INC – FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE OF NOVEMBER 28, 2018 FOR FIRDAPSE; 29/03/2018 – CATALYST SUBMITS NDA FOR FIRDAPSE

Another recent and important Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) news was published by which published an article titled: “Your Daily Pharma Scoop: 4 NDAs. CPRX, EXEL, ALPMY, ACOR” on May 31, 2018.

Investors sentiment decreased to 1.84 in Q1 2018. Its down 0.13, from 1.97 in 2017Q4. It worsened, as 16 investors sold Catalyst Pharmaceuticals, Inc. shares while 16 reduced holdings. 20 funds opened positions while 39 raised stakes. 53.38 million shares or 3.39% less from 55.25 million shares in 2017Q4 were reported. Art Advisors Ltd Co reported 109,954 shares or 0.01% of all its holdings. Royal Bancshares Of Canada reported 165,090 shares. Vantage Advisors Lc has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 3,000 shares. Bnp Paribas Arbitrage Sa reported 17,618 shares stake. Wells Fargo Mn holds 42,601 shares or 0% of its portfolio. Strs Ohio owns 223,100 shares. New York State Common Retirement Fund accumulated 74,994 shares or 0% of the stock. Consonance Capital Mngmt L P owns 4.99 million shares. California Public Employees Retirement Sys has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Caxton holds 0.1% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 36,079 shares. Element Capital Mngmt Ltd Co stated it has 10,843 shares. New York-based Berson And Corrado Advsr has invested 0.07% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Raymond James Finance Services Advsrs invested in 236,901 shares or 0% of the stock. Prudential Fincl accumulated 173,670 shares or 0% of the stock. Jbf Capital holds 458,600 shares or 0.17% of its portfolio.

Eclipse Resources Corporation (NYSE:ECR) Institutional Positions Chart